title: Nephrotoxic effects of immunosuppressant therapy in pediatric liver transplant recipients.
abstract: Drugs used for immunosuppression have been implicated in causing numerous long-term side effects including nephrotoxicity, glucose intolerance, and hyperlipidemia. In this study, we reviewed our pediatric liver transplant recipients in terms of glomerular filtration rate (GFR) as well as fasting glucose and lipid profiles. To date, 79 pediatric liver transplantations have been performed at our center: 24 transplantations of at least 5 months to a maximum of 7.3 years posttransplant are reviewed herein. The mean time posttransplantation was 2.1 years. Nine boys and 15 girls showed a distribution of 19 mixed race, 3 black, and 2 white patients. The mean age at the time of transplantation was 6.6 years (0.8-13.3 years) with 8 cases under the age of 3 years. All recipients started with Cyclosporine Neoral (CSA) as first line, but, at the time of testing, immunosuppression included 5 children on CSA and 19 on Tacrolimus. Radionuclide 51 Cr-EDTA Glomerular Filtration Rates (GFR) showed a range from 21 to 220 mL/min/1.73 m2 (mean 96.1, median 89.8). Seven cases had a GFR less than 75 mL/min/1.73 m2. Twenty-one children were on antihypertensives agents: 15 children on 1 agent and 6 children on 2 agents. On full fasting lipid profiles, the total cholesterol ranged from 2 to 7.9 mmol/L (mean 4.4). Only 1 child is currently on statin therapy. Fasting glucose ranged from 3.2 to 5.9 mmol/L (mean 4.1) No difference was observed in glucose values between CsA and Tacrolimus. Thus, immunosuppressive therapies, such as the calcineurin inhibitors, are known to cause nephrotoxicity, which is of concern in pediatric liver transplant recipients. Almost all our patients currently require antihypertensive therapy. At present, the renal function is adequate in the majority of the group, but this study needs to be extended to other pediatric liver transplant recipients with particular emphasis on those who are more than 5 years posttransplantation.
authors.affiliation: Red Cross Children's Hospital and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa. mccull@ich.uct.ac.za
authors.forename: M I
authors.initials: MI
authors.lastname: McCulloch
authors.forename: H
authors.initials: H
authors.lastname: Burger
authors.forename: C W N
authors.initials: CW
authors.lastname: Spearman
authors.forename: L
authors.initials: L
authors.lastname: Cooke
authors.forename: E
authors.initials: E
authors.lastname: Goddard
authors.forename: P
authors.initials: P
authors.lastname: Gajjar
authors.forename: A
authors.initials: A
authors.lastname: Numanoglu
authors.forename: H
authors.initials: H
authors.lastname: Rode
authors.forename: D
authors.initials: D
authors.lastname: Kahn
authors.forename: A J W
authors.initials: AJ
authors.lastname: Millar
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007223:Infant; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D011184:Postoperative Period; D012189:Retrospective Studies
chemical_list: D007166:Immunosuppressive Agents